Discussion
Graviton Bioscience has launched a Phase 2 clinical trial to test its experimental therapy GV101 in people with Friedreich’s ataxia (FA). The trial (NCT07870590) is planned to enroll 48 people with FA, ages 16 to 40, who are able to walk (with or without assistance) and who…
